Breaking News on Biopharmaceutical Development & Manufacturing

Top Headlines

Remsima's US FDA review held back by contradictory demands, says Celltrion

Contradictory requests from the US FDA on the statistical analysis of Remsima are one of many regulatory hurdles facing biosimilar developers, according to Celltrion.

US FDA's statistical analysis demands contradictory, says Celltrion

Biomay to use VTU's yeast-based tech for its allergen pipeline

Biomay has licensed a yeast-based expression system from fellow Austrian biotech VTU Technologies to use for the commercial production of its recombinant allergens.

CROs look to buttress research models businesses with CRISPR/Cas tech

As the largest pharma and tech suppliers – from Novartis to GE Healthcare to Thermo Fisher – begin exploring the world of CRISPR/Cas gene editing technology, contract research organizations are also looking into the new tech to explore ways to help clients’ research models.

Draft guidance stresses need for quality in development of gene therapies

The EMA has released draft guidelines to aid the gene therapy developers, many of which it says are small companies not familiar with the regulatory environment.

Thermo Fisher's $15bn war chest set to further consolidate industry

Danaher's acquisition of Pall will not change the competitive landscape in the bioprocessing tech industry says Thermo Fisher, as it earmarks $10bn for further M&A activity.

US scientists vow to answer CRISPR’s sticky moral questions

Top science academics have launched an initiative to consider emerging human gene-editing tools such as CRISPR-Cas9.

Key Industry Events


Access all events listing

Our events, Shows & Conferences...